Formosa Pharmaceuticals, Inc.
Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing APP13007 that is in Phase III clinical trial for the treatment of post-operative pain and inflammatory eye conditions; TSY-110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resi… Read more
Formosa Pharmaceuticals, Inc. (6838) - Total Assets
Latest total assets as of September 2025: NT$2.11 Billion TWD
Based on the latest financial reports, Formosa Pharmaceuticals, Inc. (6838) holds total assets worth NT$2.11 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Formosa Pharmaceuticals, Inc. - Total Assets Trend (2021–2024)
This chart illustrates how Formosa Pharmaceuticals, Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Formosa Pharmaceuticals, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Formosa Pharmaceuticals, Inc.'s total assets of NT$2.11 Billion consist of 81.8% current assets and 18.2% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 20.2% |
| Accounts Receivable | NT$0.00 | 0.0% |
| Inventory | NT$2.89 Million | 0.1% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Formosa Pharmaceuticals, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Formosa Pharmaceuticals, Inc.'s current assets represent 81.8% of total assets in 2024, an increase from 34.1% in 2021.
- Cash Position: Cash and equivalents constituted 20.2% of total assets in 2024, down from 30.3% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 0.1% of total assets.
Formosa Pharmaceuticals, Inc. Competitors by Total Assets
Key competitors of Formosa Pharmaceuticals, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Formosa Pharmaceuticals, Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Formosa Pharmaceuticals, Inc. generates 0.07x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Formosa Pharmaceuticals, Inc. is currently not profitable relative to its asset base.
Formosa Pharmaceuticals, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.57 | 9.31 | 9.31 |
| Quick Ratio | 9.55 | 9.31 | 9.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$1.38 Billion | NT$ 1.56 Billion | NT$ 1.56 Billion |
Formosa Pharmaceuticals, Inc. - Advanced Valuation Insights
This section examines the relationship between Formosa Pharmaceuticals, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.65 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 22.3% |
| Total Assets | NT$2.11 Billion |
| Market Capitalization | $65.78 Million USD |
Valuation Analysis
Below Book Valuation: The market values Formosa Pharmaceuticals, Inc.'s assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Formosa Pharmaceuticals, Inc.'s assets grew by 22.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Formosa Pharmaceuticals, Inc. (2021–2024)
The table below shows the annual total assets of Formosa Pharmaceuticals, Inc. from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$2.11 Billion | +22.32% |
| 2023-12-31 | NT$1.73 Billion | +96.69% |
| 2022-12-31 | NT$877.91 Million | +27.47% |
| 2021-12-31 | NT$688.72 Million | -- |